1999
Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass
Fitch J, Rollins S, Matis L, Alford B, Aranki S, Collard C, Dewar M, Elefteriades J, Hines R, Kopf G, Kraker P, Li L, O’Hara R, Rinder C, Rinder H, Shaw R, Smith B, Stahl G, Shernan S. Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass. Circulation 1999, 100: 2499-2506. PMID: 10604887, DOI: 10.1161/01.cir.100.25.2499.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBlood Loss, SurgicalCardiopulmonary BypassCognition DisordersComplement ActivationComplement C5Complement Membrane Attack ComplexCoronary Artery BypassCoronary DiseaseCreatine KinaseHumansInflammationIsoenzymesMiddle AgedMyocardial Reperfusion InjuryPostoperative ComplicationsProspective StudiesPsychological TestsSingle-Chain AntibodiesConceptsMini-Mental State ExaminationPathological complement activationCardiopulmonary bypassBlood lossMyocardial injuryC5 inhibitionTissue injuryCoronary artery bypass graft surgeryComplement inhibitorsArtery bypass graft surgeryComplement activationCognitive deficitsSingle-chain antibodyC5 complement inhibitorNew cognitive deficitsSignificant dose-dependent inhibitionBypass graft surgeryPostoperative blood lossPostoperative myocardial injurySystemic inflammatory responseComplement-mediated inflammationLeukocyte CD11b expressionNovel therapeutic strategiesComplement hemolytic activityDose-dependent fashionSelective blockade of membrane attack complex formation during simulated extracorporeal circulation inhibits platelet but not leukocyte activation
Rinder CS, Rinder HM, Smith MJ, Tracey JB, Fitch J, Li L, Rollins SA, Smith BR. Selective blockade of membrane attack complex formation during simulated extracorporeal circulation inhibits platelet but not leukocyte activation. Journal Of Thoracic And Cardiovascular Surgery 1999, 118: 460-466. PMID: 10469960, DOI: 10.1016/s0022-5223(99)70183-2.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalBlood PlateletsComplement ActivationComplement C3aComplement C8Complement Membrane Attack ComplexEnzyme-Linked Immunosorbent AssayExtracorporeal CirculationFlow CytometryHumansLeukocyte CountLeukocyte ElastaseMacrophage-1 AntigenNeutrophil ActivationNeutrophilsPlatelet ActivationPlatelet CountP-SelectinReference ValuesConceptsNeutrophil activationExtracorporeal circuitExtracorporeal circulationLeukocyte activationMembrane attack complexPlatelet activationC5b-9C5b-9 generationAttack complexC5b-9 formationMembrane attack complex formationPlatelet CD62PControl circulationCardiopulmonary bypassLate complement componentsPlatelet countMonocyte countInhibits plateletSelective blockadeLoss of monocytesExtracorporeal modelSC5b-9Complement activationComplement componentsCellular activation
1995
Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation.
Rinder CS, Rinder HM, Smith BR, Fitch JC, Smith MJ, Tracey JB, Matis LA, Squinto SP, Rollins SA. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. Journal Of Clinical Investigation 1995, 96: 1564-1572. PMID: 7657827, PMCID: PMC185782, DOI: 10.1172/jci118195.Peer-Reviewed Original ResearchConceptsCardiopulmonary bypassExtracorporeal circulationSerum complement hemolytic activityComplement activationComplement componentsP-selectin-positive plateletsC5 complement componentNeutrophil CD11b upregulationSystemic inflammatory responseBlockade of C5aComplement hemolytic activityC5b-9 generationNeutrophil activationCD11b upregulationControl MAbInflammatory responseTherapeutic interventionsPlatelet activationCellular activationC5b-9BypassC5aC3a generationConjugate formationPlatelets